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Perinatal asphyxia (PA) is an obstetric complication associated with an impaired
gas exchange. This health problem continues to be a determinant of neonatal
mortality and neurodevelopmental disorders. Palmitoylethanolamide (PEA) has exerted
neuroprotection in several models of brain injury and neurodegeneration. We aimed at
evaluating the potential neuroprotective role of PEA in an experimental model, which
induces PA in the immature rat brain. PA was induced by placing Sprague Dawley
newborn rats in a water bath at 37◦C for 19min. Once their physiological conditions
improved, they were given to surrogate mothers that had delivered normally within
the last 24 h. The control group was represented by non-fostered vaginally delivered
pups, mimicking the clinical situation. Treatment with PEA (10 mg/kg) was administered
within the first hour of life. Modifications in the hippocampus were analyzed with
conventional electron microscopy, immunohistochemistry (for NeuN, pNF-H/M, MAP-2,
and GFAP) and western blot (for pNF H/M,MAP-2, and GFAP). Behavior was also studied
throughout Open Field (OF) Test, Passive Avoidance (PA) Task and Elevated Plus Maze
(EPM) Test. After 1 month of the PA insult, we observed neuronal nucleus degeneration
in CA1 using electron microscopy. Immunohistochemistry revealed a significant increase
in pNF-H/M and decrease in MAP-2 in CA1 reactive area. These changes were also
observed when analyzing the level of expression of these markers by western blot.
Vertical exploration impairments and anxiety-related behaviors were encountered in the
OF and EPM tests. PEA treatment attenuated PA-induced hippocampal damage and its
corresponding behavioral alterations. These results contribute to the elucidation of PEA
neuroprotective role after PA and the future establishment of therapeutic strategies for
the developing brain.
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INTRODUCTION
Perinatal asphyxia (PA) is an obstetric complication occurring
when oxygen supply to the newborn is temporally interrupted
(Adcock and Papile, 2008). This health problem remains as
a condition of high prevalence (1 to 10/1000 live births)
worldwide (Douglas-Escobar and Weiss, 2015). PA continues
to be a determinant of neurological morbidity (Morales et al.,
2011). If the region affected is immature, the insult interferes
with the initial plastic changes necessary for the establishment
of brain circuitries (Herrera-Marschitz et al., 2014). Several
neurodevelopmental disorders (NDDs) have been associated
with PA, including Attention Deficit Disorder (Perna and
Cooper, 2012), Autism Spectrum Disorder (Schieve et al.,
2014; Fezer et al., 2017) and distinct learning disorders
(van Handel et al., 2007). Symptomatology becomes apparent
during childhood, as environmental demands increase (Herrera-
Marschitz et al., 2017).
An experimental model of PAwas established several years ago
(Bjelke et al., 1991). This rat model of global asphyxia involves
the submersion of pup containing uterine horns in a water bath
immediately after caesarean section, mimicking delayed labor.
This method presents other translational advantages (Barkhuizen
et al., 2017; Herrera et al., 2017; Herrera-Marschitz et al., 2017),
such as the induction of PA at a time point when rodent
brain maturity resembles the brain of a human fetus at 22–32
gestational weeks (Semple et al., 2013). This aspect is of clinical
relevance since prematurity is associated with PA and increases
the risk of neurological morbidity (Kuzniewicz et al., 2014). In the
last 26 years, this murinemodel contributed to scientific advances
on the neuropathological, functional (Barkhuizen et al., 2017)
and synaptic effects of PA on the CNS (Herrera et al., 2017),
and onmechanisms of neuroprotection (Herrera-Marschitz et al.,
2011; Muñiz et al., 2014). Research on neuroprotection is based
on the concept of secondary lesion, which offers a therapeutic
window for early intervention (Blanco et al., 2011).
Palmitoylethanolamide (PEA) is an endogenous lipid
compound derived from the reaction between ethanolamine
and palmitic acid (Guida et al., 2017a). PEA is member of the
N-acylethanolamides (NAEs) family, characterized for inhibiting
mechanisms of secondary injury (Ahmad et al., 2012a). This pro-
homeostatic mediator (Petrosino et al., 2010; Petrosino and Di
Marzo, 2017) exerted neuroprotective effects when administered
exogenously in models of brain injury and neurodegeneration
(Herrera et al., 2016), including spinal cord injury (Genovese
et al., 2008; Esposito et al., 2011), traumatic brain injury (Ahmad
et al., 2012a; Guida et al., 2017a), stroke (Ahmad et al., 2012b),
Alzheimer’s Disease (D’Agostino et al., 2012; Scuderi et al.,
2014), and Parkinson’s Disease (Esposito et al., 2012). These
effects are apparently mediated by the nuclear Peroxisome
Proliferator-Activated Receptor (PPAR)-α (Lo Verme et al.,
2005).
Recent studies from our laboratory reported a dysregulation of
NAEs signaling system in rat hippocampus at post-natal day 30
(P30) after PA, and suggested PEA might exert neuroprotective
effects when administered exogenously (Blanco et al., 2015).
P30 constitutes an interesting time point for testing the effect
of neuroprotective agents since it is equivalent to 4–11 human
years (Semple et al., 2013), a period of NDDs onset (Herrera-
Marschitz et al., 2014, 2017). In addition, the hippocampus
represents a brain region of major vulnerability to PA (Petito
and Pulsinelli, 1984; Pulsinelli, 1985; Van de Berg et al., 2000)
and of considerable implication in the pathophysiology of NDDs
(Rojas et al., 2004; Saraceno et al., 2016). Therefore, the aim of the
present work was to study the neuroprotective role of PEA in rat
hippocampus at P30 after PA, contributing to the establishment
of treatments for PA and the consequent prevention of NDDs.
MATERIALS AND METHODS
All procedures were approved by the Institutional Animal
Care and Use Committee at the University of Buenos Aires
(CICUAL#4091/04) and conducted according to the principles of
the Guide for the Care and Use of Laboratory Animals (Animal
Welfare Assurance, A-3033-01/protocol#S01084).
Animals
Subjects consisted of 20 pregnant Sprague Dawley rats obtained
from the central vivarium at the School of Veterinary Sciences,
Universidad de Buenos Aires. Animals arrived 1 week prior
to delivery to our local vivarium in order to acclimate to the
new environment. They were housed in individual cages with
constant temperature (21 ± 2◦C) and humidity (65 ± 5%)
conditions. A light/dark cycle of 12:12 h was employed. The light
period began at 7 a.m. Food and tap water were provided.
Induction of PA
Rat pups were subjected to PA using the experimental model
originally developed by Bjelke et al. (1991) and modified in our
laboratory (Capani et al., 2009). At the expected day of delivery,
gestational day 22, pregnant rats were observed and when the
first pup was delivered, the dam was immediately euthanized
by decapitation. Uterine horns were rapidly isolated through an
abdominal incision, and submerged in a water bath at 37◦C for
19min, inducing severe asphyxia.When time elapsed, horns were
rapidly opened and pups were subjected to tactile intermittent
stimulation until regular breathing was established. Umbilical
cord was tied and the animals were left to recover 1 h under a
heat lamp.
Protocol of Neuroprotection
Sixty-three male rat pups were treated with PEA or vehicle (VHI)
in a dose of 10 mg/kg by subcutaneous injection. This dose has
shown effective results in several models of brain injury and
neurodegeneration (Genovese et al., 2008; Esposito et al., 2011,
2012; Ahmad et al., 2012a,b; Sayd et al., 2014; Scuderi et al.,
2014). The respective treatment was performed within the first
hour of life. VHI used was 1:1:8 DMSO, Tween 80 and NaCl.
The formulation of PEA tested was C18H37NO2 from Tocris
Bioscience (Bristol, UK). This formulation crosses the blood-
brain barrier because it is proven that this compound possess
neuromodulatory effects in vivo through inhibition of nicotine-
induced excitation on dopamine neurons in the ventral tegmental
area of rats (Melis et al., 2008). Besides, this compound exhibits
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antinociceptive, antiepileptic and anticonvulsant properties
in vivo (Lambert et al., 2001; Sheerin et al., 2004). On the other
hand, it is widely accepted that this PEA formulation is involved
in the modulation of neuroinflammation produced in the central
nervous system (Sayd et al., 2014). It has shown to be useful in
the control of neuropathic pain (Re et al., 2007) and it could
exert neuroprotective properties in neurological disorders such
as stroke (Ahmad et al., 2012b), traumatic brain injury (Ahmad
et al., 2012a), Alzheimer and Parkinson’s disease (D’Agostino
et al., 2012; Esposito et al., 2012) or addiction (Coppola and
Mondola, 2013).
Once pups improved their physiological conditions, they were
given to surrogate mothers that had delivered normally within
the last 24 h. Four experimental groups were established: rats
subjected to PA and injected with VHI (PA group, n = 15), rats
born vaginally and injected with VHI (control – CTL- group,
n = 13), rats subjected to PA and injected with PEA (PA+PEA
group, n = 18) and rats born vaginally and injected with PEA
(CTL+PEA group, n = 17). The different groups were marked
and mixed in litters with a surrogate mother. After weaning,
rats were housed in cages of 3–4 animals from the same group.
Cesarean controls were not used since previous studies revealed
this group did not present significant differences with vaginal
controls (Galeano et al., 2011; Blanco et al., 2015).
Behavioral Testing
General Procedure
At P30, rats (N = 63) were subjected to behavioral tests in an
isolated behavioral room from 8 a.m. to 5 p.m. In order to avoid
the confounding effect of time of day, testing order of the groups
was counterbalanced. The apparatus of each test was cleaned
with 70 % ethanol between sessions to minimize the olfactory
stimulus. White noise was provided during tests (Galeano et al.,
2015). Before any of the tests, the assessed rat was placed in
the behavioral room for acclimatization during 5min (Molina
et al., 2016). In this way, potential confounding variables were
controlled. The following tests were performed.
Elevated Plus Maze (EPM) Test
The EPM test evaluates anxiety-related behaviors, which are
hippocampal dependent (Montgomery, 1955; Brenes et al., 2009;
Violle et al., 2009;Molina et al., 2016). The apparatus wasmade of
black melamine and consisted of a central square platform (11×
11 cm). Four illuminated arms radiated from this platform: two
closed arms (50 × 11 × 40 cm) and two open arms (50 × 11 ×
0.25 cm), conforming a maze in the shape of a plus. This maze
was elevated to a height of 100 cm above floor-level (Galeano
et al., 2015). Procedure: The test began by placing the rat on
the central platform facing an open arm. The rat was allowed to
freely explore the apparatus for 5min. When time elapsed, the
rat was removed from the apparatus and returned to the home
cage. A rat was considered to enter an arm when its 4 paws were
inside (Galeano et al., 2015). Total distance traveled and time
spent in closed arms were quantified as indicators of locomotion.
Time spent in open arms was measured in order to assess anxiety
levels. The stretching of rats over the edge of an open arm, known
as head-dipping (HD), was also recorded as a risk-assessment-
behavior (RAB) (Rodgers and Cole, 1993; Molina et al., 2016).
Prototypical behaviors, rearing and grooming, were assessed.
Time spent rearing was recorded as a hippocampal-dependent
indicator of vertical exploration (Lever et al., 2006). Rats that
fell down from the maze during testing were excluded from
the study. Testing sessions were filmed using a digital camera
(Sony HDR-AS100V) and later analyzed with ANY-Maze video-
tracking software (version 5.29). Rearing, grooming andHDwere
registered by blind evaluation and time was quantified using the
key resource of ANY-Maze.
Open Field (OF) Test
The OF test was used to assess locomotion, exploratory activity
and changes in emotionality induced by exposure to a novel
environment (Molina et al., 2016). These behavioral parameters
also depend on hippocampal integrity (Vianna et al., 2000; Barros
et al., 2006; Molina et al., 2016). The apparatus consisted of
a black melamine square (60 × 60 × 40 cm) surrounded by
walls of 40 cm high (Galeano et al., 2015). Procedure: Rats were
placed on the center of the apparatus and allowed to explore
it for 5min. (Molina et al., 2016). Total distance traveled and
number of line crossings were quantified in order to measure
locomotion. Prototypical behaviors, rearing and grooming, were
assessed. Time spent rearing was recorded as a hippocampal-
dependent indicator of vertical exploration (Lever et al., 2006).
Testing sessions were filmed using a digital camera (Sony HDR-
AS100V) and later analyzed with ANY-maze video-tracking
software (version 5.29). Rearing and grooming were registered by
blind evaluation and time was quantified using the key resource
of ANY-maze.
Inhibitory Avoidance (IA) Task
The IA task measures memory of an aversive experience
through the avoidance of a location where an unpleasant
experience occurred (Molina et al., 2016; Saraceno et al., 2016).
This parameter constitutes an indicator of associative memory,
which is hippocampal-dependent (Ennaceur and Delacour, 1988;
Lorenzini et al., 1996; Izquierdo and Medina, 1997; Molina et al.,
2016). The apparatus consisted of a black melamine square (60×
60× 40 cm) divided into two compartments: one was illuminated
and the other was dark. A removable cover was used for this
purpose. The floor of the dark compartment was made of a
stainless steel grid, which could deliver an electric shock when
pressing a button. Procedure: The test was divided in three
sessions. The habituation session consisted of placing the rat in
the illuminated compartment. After entering the dark section
three times, the rat was removed from the apparatus. If the rat did
not enter the dark side three times, it was removed after the three-
minute trial was completed. The next trial was performed after
10min by placing the rat again in the lit compartment. When
it entered the dark section, doors were closed retaining the rat
for 10 s inside this compartment. The training session took place
after an hour. The rat was placed in the illuminated section and
the latency to enter the dark side was registered. As soon as the
rat entered the dark compartment, an electric shock (1.2mA, 2s)
was delivered. Then, the rat was returned to its home cage. One
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hour later, the rat was placed in the lit compartment but this time
the electric shock was not delivered. This is the retention session,
when the latency to enter the dark side is again measured. The
ratio between the latency to enter the dark compartment in the
retention (T2) and the training session (T1), which is expressed
as T2/T1, constitutes an indicator of aversive associative memory
(Molina et al., 2016).
Order of Testing
Tests were performed in the order they were described above.
As the EPM test is specific for measuring anxiety, it was
performed firstly, in order to avoid the confounding effect of
previous tests. Inversely, the IA task was administered at the end
because the aversive effect of the electric shock could constitute a
confounding variable for following tests.
Tissue Fixation and Immunohistochemistry
At P30, intracardiac perfusion and coronal hippocampal sections
were performed as described previously (Saraceno et al.,
2016). Four animals per treatment (four replicates) were used.
Three sections were immunostained for each analyzed brain.
Animals were anesthetized with intraperitoneal administration
of ketamine 40 mg/kg and xylazine 5 mg/kg, and perfused
intracardiacally with 4% paraformaldehyde in 0.1M phosphate
buffer, pH 7.4. Brains were removed and post-fixed in the same
fixative solution for 2 h at room temperature, and then immersed
overnight at 4◦C in 0.1M phosphate buffer, pH 7.4. Coronal
hippocampal sections (50µm thickness) were obtained using a
Vibratome (VT 1000 S, Leyca Microsystems, Wetzlar, Germany).
Immunohistochemistry was performed on free-floating sections
under moderate shaking. Endogenous peroxidase was quenched
(3% H2O2, 70% methanol, 30% H2O2 30 vol) and non-specific
labeling was blocked using 0.3% normal goat serum. Free-
floating sections were incubated overnight at 4◦C with anti-
neuron-specific nuclear protein (NeuN; 1:1,000, mouse-IgG;
Millipore), anti-microtubule-associated protein 2 (MAP-2; 1:250,
polyclonal rabbit-IgG; Abcam), anti-phosphorylated high and
medium molecular weight neurofilaments (pNF H/M; 1:500,
monoclonal mouse-IgG; Millipore) or anti-glial fibrillary acidic
protein (GFAP; monoclonal rabbit IgG, 1:200, Cell Marque,
a Sigma-Aldrich Company). Then sections were incubated
for 2 h at room temperature (RT) with secondary antibodies
(Biotinylated anti-mouse-IgG, 1:500, Vector; Biotinylated anti-
rabbit-IgG, 1:500, Vector). Amplification was done using avidin-
biotinylated horseradish peroxidase complex (1:500, Dako) in
PBS for 1 h, followed by washing in PBS before chromogen
development (DAB; Cell Marque, a Sigma-Aldrich Company).
Light microscopic images were obtained (using a Leyca
microscopy).
Electron Microscopy Procedure
Coronal brain sections of four animals were cut at a
thickness of 40µm with a vibratome through the level
of the dorsal neostriatum and post-fixed for 1 h with 4%
paraformaldehyde in 0.1M cacodylate buffer, pH 7.4. Then,
tissue sections from hypoxic and control animals were stained
by conventional osmium–uranium–lead method, following the
protocol described in Capani et al. (2001). Thin sections (50-
80 nm) were cut with Reichert Ultracut E by using glass knives.
Sections were counterstained with a combination of lead citrate.
Thin sections were examined using a JEOL 200CX electron
microscope at 80–100 keV.
Morphometric Analysis
One hundred fifty by 150µmwas sampled in each photo in order
to estimate the percentage of reactive area for pNF-H/M and
MAP-2 using Image J Program (Image J 1.41o, NIH, USA). We
focused our analysis on CA1 area of hippocampus since it is one
of the most affected areas by PA insult (Petito and Pulsinelli,
1984; Pulsinelli, 1985; Van de Berg et al., 2000). The number
of GFAP immunoreactive astrocytes was estimated manually
in the stratum radiatum of CA1 hippocampal area. A total of
80 counting frames was assessed per animal. A blind observer
selected 5 fields for each sector from 4 sections of striatum and 10
fields of cortex from 10 sections (two hundred fields of striatum
and 200 fields of cortex). To estimate the percentage of reactive
area the experiments were repeated at least 3 times.
Western Blot
Western blot analysis was performed using four animals per
treatment (four replicates). Experiments were repeated three
times for each brain. Animals were euthanized by decapitation,
brains were dissected, homogenized in ice-cold lysis buffer
(10mM Tris/HCl, pH 7.4, 10mM NaCl, 3mM MgCl2, 0.1%
Triton X-100, protease inhibitors). Tissues were thawed on
ice and centrifuged at 14,000 rpm for 15min at 4◦C. The
supernatants were analyzed for total protein concentration
using Bradford solution (Bio-Rad, Richmond CA, USA) in 96-
well plates using bovine serum albumin (BSA) as standard.
90 µg of total protein were diluted in sample buffer (0.3M
Tris/HCl, pH 7, 50% glycerol, 5%SDS, 1mM EDTA, 0.1%
bromophenol blue). The samples were subjected to SDS-PAGE
using the Mini-protein II cell (Bio-Rad, Richmond CA, USA)
with precast 4–20% Precise gels (Bio-Rad, Richmond CA, USA).
Proteins were transferred to PVDF membranes (MACHEREY-
NAGEL, Germany) using the semi-dry transfer unit Hoefer
TE 70 (Amersham Biosciences). Membranes were blocked
with 5% non-fat milk powder and 1% BSA in Tris-buffered
saline containing 0.05% Tween 20 and incubated overnight
at 4◦C with anti-microtubule-associated protein 2 (MAP-2;
1:1,000, polyclonal rabbit-IgG; Abcam), anti-phosphorylated
high and medium molecular weight neurofilaments (pNF-H/M;
1:500, monoclonal mouse-IgG; Millipore) and anti-glial fibrillary
acidic protein (GFAP; monoclonal mouse-IgG, 1:1,000; Santa
Cruz Biotechnology). We used anti glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, 1:1,000, rabbit-IgG, Sigma-Aldrich)
as loading control. Blots were rinsed three times in PBS
with 0.5% Tween-20 buffer (PBST), and then incubated with
the corresponding horseradish peroxidase (HRP)-conjugated
secondary antibody (1:3,000,Bio-Rad, Richmond CA, USA) for
1 h at RT. Immunoreactive bands were detected using an ECL
western blotting analysis system (clarity western ECL substrate,
Bio-Rad). Films were scanned and the optical density of protein
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bands was quantified using Gel Pro Analyzer 3.1.00.00 (Media
Cybernetics).
Statistical Analysis
Results were expressed as means ± SEM. Normal distribution
and equality of variances were checked using Shapiro-Wilk test
and Levene’s test, respectively. Statistical analyses were conducted
by two-way analysis of variances (ANOVAs) with birth condition
(CTL and PA) and treatment (VHI and PEA) as the main
factors. When interaction effects were significant, analyses were
performed by post hoc comparisons using Student’s t-test (two-
tailed) adjusted by Bonferroni correction. Differences with a
probability of 5% or less were considered to be significant.
Statistical analysis was carried out using Graph pad Prism 5
program.
RESULTS
Vulnerability of CA1 Hippocampal Neurons
to PA. Effects of PEA Treatment
Nuclear morphology was analyzed to evaluate the vulnerability
of CA1 neurons at the stratum radiatum of rat hippocampus
at P30 (Figure 1; Table 1). We observed a significant increase
(F = 2142, p < 0.05) in the number of pyknotic nucleus
in the hippocampal CA1 neurons layer of asphyctic animals
(Table 1). In addition, the number of pyknotic nucleus was
significantly reduced in the PA+PEA group (F = 1978, p < 0.05)
(Table 1). Then we analyzed NeuN+ neurons and classified
them in two categories: (a) normal neurons, characterized by
an intense NeuN+ nucleus and (b) abnormal neurons, with
NeuN fragmentation of the nucleus, or cytoplasmic staining
without nuclear staining (Robertson et al., 2006). We observed
a significant increase in the number of abnormal neurons in the
hippocampal CA1 layer of asphyctic animals (F= 2036, p< 0.05)
(Table 1; Figures 1A,B). PEA treatment improved significantly
nucleus alterations (F = 1936, p < 0.05) (Table 1; Figures 1B,D).
Electron microscopy analyses showed clear degeneration of
CA1 neurons after PA (Figures 1E,F), which was reduced after
treatment with PEA (Figures 1F–H). Altogether, these results
indicate that major PA effects occurred on CA1 neurons and
could be ameliorated by PEA treatment.
PA-Induced Alterations in pNF-H/M.
Protective Effect of PEA Treatment
The accumulation of pNF-H/M as a measure of axonal
dysfunction and degeneration was analyzed by immunostaining.
Figure 2A shows a representative example of the stratum
radiatum of CA1 hippocampal section immunostained for pNF-
H/M. The two-way ANOVA revealed that the main factors
of birth condition and treatment were both significant when
analyzing the percentage of reactive area for pNF-H/M (F= 2033,
p < 0.0001; F = 509.8, p < 0.0001, respectively), and the
TABLE 1 | Damage of CA1 hippocampal neurons after PA and effect of PEA
treatment.
Groups Pyknotic
nuclei
NeuN +
neurons
Normal
neurons
Abnormal
neurons
CTL 13.24 ± 1.42 76.35 ± 1.56 71.24 ± 0.33 5.11 ± 0.51
PA 20.96 ± 0.21* 64.24 ± 3.54 53.44 ± 0.82 10.8 ± 0.71*
CTL+PEA 12.34 ± 1.33 73.23 ± 2.32 69.25 ± 0.93 5.98 ± 0.43
PA+PEA 15.36 ± 1.97 67.26 ± 2.48 63.35 ± 0.72 7.91 ± 0.64
Data expressed asmean± SD. Statistical differences were assessed by two-way ANOVA.
*P < 0.05.
FIGURE 1 | Neuronal alterations induced by PA and recovery after PEA treatment. (A-D) Micrographs of Stratum radiatum of CA1 hippocampal area in the different
groups analyzed by NeuN Immunostaining. (E–H). Electron microscopy (EM) of CA1 neurons showing that most of the condensed cells correspond to neurons in
degeneration. Statistical analysis of different parameters was performed. Significant differences were calculated by two-way analysis of variances (ANOVAs) tests
followed by post hoc comparisons using Student’s t-test (two-tailed) adjusted by Bonferroni correction.
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FIGURE 2 | pNF-H/M immunostaining and protein expression levels in the rat hippocampus. PEA treatment attenuated increased pNF-H/M expression after PA.
(A) Representative image of the striatum radiatum of CA1 hippocampal area immunostained for pNF-H/M in the different groups. (B) The statistical analysis revealed a
significant increase in the percentage of reactive area of pNF-H/M inmunostaining in PA rats treated with vehicle (PA) in comparison to CTL rats treated with vehicle
(CTL), and a significant decrease in the percentage of reactive area of pNF-H/M inmunostaining in PA rats treated with PEA (PA+PEA) in comparison to PA rats treated
with vehicule (PA), suggesting a partial reversion of axonal dysfunction and degeneration associated with perinatal asphyxia, although PA+PEA group did not reach
values similar to controls. PEA by itself did not produce any differences in the percentage of reactive area of pNF-H/M inmunostaining, since CTL+PEA rats did not
differ from CTL rats. (C) Consistent with these morphological observations, results similar to those of the percentage of reactive area were observed by western blot in
protein expression levels of pNF-H/M. Bars and error bars represent mean + SEM calculated by two-way analysis of variances (ANOVAs) tests followed by post hoc
comparisons using Student’s t-test (two-tailed) adjusted by Bonferroni correction. **P < 0.001, PA vs. CTL; ##P < 0.001, PA vs. PA+PEA; &&P < 0.001, PA+PEA
vs. CTL.CTL, Control group; PA, rats subjected to PA; PA+PEA, rats subjected to PA and PEA treatment; CTL+PEA, control group subjected to PEA treatment.
interaction was also significant (F = 604.8, p < 0.0001). Post hoc
analysis of the simple effects indicated that the reactive area for
pNF-H/M at P30 showed a significant increase as a consequence
of PA (t = 49.27, p < 0.001) (Figure 2B). This alteration was
significantly attenuated in PA+PEA group (t= 31.54, p< 0.001),
although this group did not reach values similar to controls
(t = 14.49, p < 0.001) (Figure 2B). Consistent with these
morphological observations, birth condition and treatment were
significant with respect to protein expression for pNF-H/M
(F = 2494, p < 0.0001; F = 517.9, p < 0.0001, respectively).
The interaction was also significant (F = 477.1, p < 0.0001).
An increase in pNF-H/M expression was observed in PA group
(t = 50.76, p < 0.001), and reduced after PEA treatment
(t = 13.66, p < 0.001) (Figure 2C). However, PA+PEA group
still presented significant differences with controls (t = 19.87,
p < 0.001) (Figure 2C). Treatment with PEA in CTL rats had
no significant effect on both reactive area and protein expression
for pNF-H/M in comparison to CTL rats injected with VHI
(t = 0.6472, p > 0.05; t = 0.09113, p > 0.05, respectively)
(Figures 2B,C, respectively).
Dendritic Cytoskeleton Alteration and Its
Attenuation by PEA Treatment
Since PA affected neuronal population, we also studied
cytoskeleton organization of neural processes. Changes in
dendrite morphology were analyzed through immunostaining
of a dendrite-specific marker, MAP-2 (Figure 3A). According to
two-way ANOVA results for MAP-2 reactive area, both birth
condition and treatment were significant (F = 1342, p < 0.0001;
F = 72.89, p < 0.0001, respectively). The interaction was also
significant (F = 59.01, p < 0.0001). Post hoc analysis revealed the
PA group presented a significant decrease in the percentage of
MAP-2 reactive area in comparison to the CTL group (t = 31.33,
p < 0.001) (Figure 3B). This reduction in MAP-2 reactive area
was partially reversed after PEA treatment (t = 11.47, p < 0.001),
without reaching values similar to controls (t = 20.47, p < 0.001)
(Figure 3B). These morphological findings were confirmed by
western blot. Birth condition and treatment were significant
factors for MAP-2 protein expression (F = 5181, p < 0.0001;
F = 316.7, p < 0.0001, respectively), and the interaction was
significant (F = 289.7, p < 0.0001). A significant reduction
in MAP-2 expression was observed as a consequence of PA
(t = 62.93, p < 0.001) (Figure 3C). This modification was
attenuated in the PA+PEA group (t = 24.62, p < 0.001).
However, this group still presented significant differences with
controls (t = 38.86, p < 0.001) (Figure 3C). Finally, treatment
with PEA did not exert a significant effect either in MAP-2
reactive area or in protein expression when comparing CTL and
CTL+PEA groups (t = 0.6053, p > 0.05; t = 0.5479, p > 0.05,
respectively) (Figures 3B,C, respectively).
GFAP Immunostaining and Protein
Expression at P30 After PA
We used immunohistochemistry and western blot to analyze
glial response to PA injury and PEA treatment. As regards
the number of GFAP positive astrocytes, the two-way ANOVA
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FIGURE 3 | MAP-2 immunostaining and protein expression levels in the rat hippocampus. (A) Representative image of the striatum radiatum of CA1 hippocampal
area immunostained for MAP-2 in the different groups. (B) The statistical analysis revealed a significant decrease in the percentage of reactive area of MAP-2 positive
dendrites in PA rats treated with vehicle (PA) in comparison to CTL rats treated with vehicle (CTL), and a significant increase in the percentage of reactive area of
MAP-2 positive dendrites in PA rats treated with PEA (PA+PEA) in comparison to PA rats treated with vehicule (PA), suggesting a partial reversion of dendritic
alterations associated with perinatal asphyxia, although PA+PEA group did not reach values similar to controls. PEA by itself did not produce any differences in the
percentage of reactive area of MAP-2 positive dendrites, since CTL+PEA rats did not differ from CTL rats. (C) Consistent with these morphological observations,
results similar to those of the percentage of reactive area were observed by western blot in protein expression levels of MAP-2. Bars and error bars represent mean +
SEM calculated by two-way analysis of variances (ANOVAs) tests followed by post hoc comparisons using Student’s t-test (two-tailed) adjusted by Bonferroni
correction. **P < 0.001, PA vs. CTL; ##P < 0.001, PA vs. PA+PEA; &&P < 0.001, PA+PEA vs. CTL.CTL, Control group; PA, rats subjected to PA; PA+PEA, rats
subjected to PA and PEA treatment; CTL+PEA, control group subjected to PEA treatment.
indicated that birth condition and treatment were not significant
(F = 0.0009796, p = 0.9752; F = 0.02149, p = 0.884).
These results were confirmed when analyzing the expression of
GFAP. Birth condition and treatment were not significant either
(F = 1.194, p= 0.2853; F = 0.9972, p= 0.328, respectively).
Behavioral Modifications Induced by PA at
P30. Protective Role of PEA
Locomotion and general activity were not affected by PA at
P30. With respect to the number of line crossings in the OF
test, the two-way ANOVA revealed neither birth condition
(F = 1.93, p = 0.1716), nor treatment (F = 0.6706, p = 0.4172)
were significant. Similarly, birth condition and treatment were
not significant for time spent in closed arms in the EPM
test (F = 0.03662, p = 0.8493; F = 3.624, p = 0.0646,
respectively). In addition, birth condition and treatment were
not significant for total distance traveled in the OF (F = 0.8553,
p = 0.3592; F = 0.005146, p = 0.9431, respectively) and
EPM test (F = 0.1234, p = 0.7272; F = 2.645, p = 0.1119,
respectively).
In contraposition, vertical exploration might be altered at
P30 as a consequence of PA, as it can be inferred from results
in rearing, a prototypical behavior in rats. As for time spent
rearing in the OF test, the two-way ANOVA revealed that the
main factors of birth condition and treatment were significant
(F = 5.51, p = 0.0226; F = 5.779, p = 0.0197, respectively).
However, the interaction was not significant (F = 2.888,
p = 0.095). Post hoc analysis indicated PA rats showed a
significant decrease in time spent rearing with respect to the
CTL group (t = 2.838, p < 0.05). This behavioral alteration was
reversed in the PA+PEA group (t = 3.119, p < 0.01). This group
did not present significant differences with controls (t = 0.462,
p> 0.05) (Figure 4A). Similar results were found in the EPM test
as regards time spent rearing. Birth condition and treatment were
significant factors (F = 41.26, p < 0.0001; F = 10.69, p= 0.0024,
respectively), and the interaction was also significant (F = 11.67,
p = 0.0016). According to post hoc analysis of the simple effects,
a significant reduction in time spent rearing was registered as a
consequence of PA (t = 6.958, p < 0.001), and reversed after
PEA treatment (t = 4.728, p < 0.001). PA+PEA group did not
show significant differences with respect to controls (t = 2.126,
p > 0.05) (Figure 5A). Both in OF and EPM test, treatment
with PEA in CTL rats had no significant effect on time spent
rearing in comparison to CTL rats injected with VHI (t= 0.4677,
p > 0.05; t = 0.1042, p > 0.05, respectively) (Figures 4A, 5A,
respectively).
Although birth condition was not significant for time spent in
open arms in the EPM test (F= 3.203, p= 0.0813), other anxiety-
related behaviors were encountered as a consequence of PA at
P30. With regard to time spent grooming in the OF test, two-way
ANOVA revealed birth condition and treatment were significant
(F = 6.015, p = 0.0172; F = 16.64, p = 0.0001, respectively), but
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FIGURE 4 | Behavioral differences in time spent rearing and time spent
grooming between the 4 groups in the OF test. (A). The statistical analysis
revealed a significant reduction in time spent rearing in PA rats treated with
vehicle (PA) in comparison to CTL rats treated with vehicle (CTL) and PA rats
treated with PEA (PA+PEA). In addition, PA+PEA rats did not show significant
differences on time spent rearing in comparison to CTL rats, suggesting a
reversion of this behavioral alteration associated with perinatal asphyxia. PEA
by itself had no significant effect on time spent rearing, since CTL+PEA rats
did not differ in time spent rearing from CTL rats. (B) The statistical analysis
indicated time spent grooming was significantly augmented in PA rats treated
with vehicle (PA) in comparison to CTL rats treated with vehicle (CTL) and PA
rats treated with PEA (PA+PEA). In addition, PA+PEA rats did not show
significant differences on time spent grooming in comparison to CTL rats,
suggesting a reversion of this behavioral alteration associated with perinatal
asphyxia. PEA by itself had no significant effect on time spent grooming, since
CTL+PEA rats did not differ in time spent grooming from CTL rats. Bars and
error bars represent mean + SEM calculated by two-way analysis of variances
(ANOVAs) tests followed by post hoc comparisons using Student’s t-test
(two-tailed) adjusted by Bonferroni correction. *P < 0.05, PA vs. CTL;
#P < 0.01 and ##P < 0.001, PA vs. PA+PEA.CTL, Control group; PA, rats
subjected to PA; PA+PEA, rats subjected to PA and PEA treatment;
CTL+PEA, control group subjected to PEA treatment.
not the interaction (F = 3.405, p = 0.8767). Post hoc analysis
indicated time spent grooming was significantly augmented as a
result of PA (t= 2.88, p< 0.05), and reversed after PEA treatment
(t = 4303, p < 0.001). PA+PEA group did not present significant
differences with controls (t= 0.4561, p> 0.05) (Figure 4B). Time
spent grooming was also altered in the EPM test as a consequence
FIGURE 5 | Behavioral differences in time spent rearing, time spent grooming
and time spent head dipping between the 4 groups in the EPM test. (A) The
statistical analysis revealed a significant reduction in time spent rearing in PA
rats treated with vehicle (PA) in comparison to CTL rats treated with vehicle
(CTL) and PA rats treated with PEA (PA+PEA). In addition, PA+PEA rats did
not show significant differences on time spent rearing in comparison to CTL
rats, suggesting a reversion of this behavioral alteration associated with
perinatal asphyxia. PEA by itself had no significant effect on time spent rearing,
since CTL+PEA rats did not differ in time spent rearing from CTL rats. (B) The
statistical analysis indicated time spent grooming was significantly augmented
(Continued)
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FIGURE 5 | in PA rats treated with vehicle (PA) in comparison to CTL rats
treated with vehicle (CTL), but PA rats treated with PEA (PA+PEA) did not differ
on time spent grooming in comparison to PA rats treated with vehicule (PA),
suggesting that PEA did not exert a protective effect in PA rats. In addition,
PA+PEA rats presented significant differences on time spent grooming in
comparison to CTL rats. PEA by itself had no significant effect on time spent
grooming, since CTL+PEA rats did not differ in time spent grooming from CTL
rats. (C) The statistical analysis indicated time spent head dipping was
significantly augmented in PA rats treated with vehicle (PA) in comparison to
CTL rats treated with vehicle (CTL) and PA rats treated with PEA (PA+PEA). In
addition, PA+PEA rats did not show significant differences on time spent head
dipping in comparison to CTL rats, suggesting a reversion of this behavioral
alteration associated with perinatal asphyxia. PEA by itself had no significant
effect on time spent head dipping, since CTL+PEA rats did not differ in time
spent head dipping from CTL rats. Bars and error bars represent mean + SEM
calculated by two-way analysis of variances (ANOVAs) tests followed by post
hoc comparisons using Student’s t-test (two-tailed) adjusted by Bonferroni
correction. *P < 0.05 and **P < 0.001, PA vs. CTL; ##P < 0.001, PA vs.
PA+PEA; &P < 0.05, PA+PEA vs. CTL. CTL, Control group; PA, rats
subjected to PA; PA+PEA, rats subjected to PA and PEA treatment;
CTL+PEA, control group subjected to PEA treatment.
of PA, but PEA treatment did not exert a protective effect
in this case. Two-way ANOVA indicated birth condition was
significant (F= 14.15, p= 0.0007), in contraposition to treatment
(F = 0.0001407, p = 0.9906) and the interaction (F = 0.02445,
p = 0.8767). Post hoc analysis revealed time spent grooming was
significantly increased in the PA group in comparison to the CTL
group (t = 2.873, p < 0.05), but not reversed in the PA+PEA
group (t = 0.09661, p > 0.05). This group presented significant
differences with controls (t = 2.464, p < 0.05) (Figure 5B). In
both OF and EPM tests, treatment with PEA in CTL rats had
no significant effect on time spent grooming in comparison to
CTL rats injected with VHI (t = 1.54, p > 0.05; t = 0.1267,
p > 0.05, respectively) (Figures 4B, 5B, respectively). As for
time spent HD (in the EPM test), two-way ANOVA indicated
birth condition, treatment and the interaction were significant
(F = 53.33, p < 0.0001; F = 33.4, p < 0.0001; F = 34.19,
p < 0.0001, respectively). Post-hoc analysis of the simple effects
revealed time spent HD was significantly augmented in the PA
group (t = 9.781, p < 0.001), and reversed in the PA+PEA
group (t = 7.99, p < 0.001). This group did not show significant
differences with controls (t = 1.185, p > 0.05). No significant
differences were found between CTL and CTL+PEA groups
either (t = 0.04995, p > 0.05) (Figure 5C).
Finally, aversive associative memory might not be affected at
P30 as a consequence of PA. Two-way ANOVA revealed birth
condition was not significant with respect to T2/T1 ratio from
the IA task (F = 0.854, p= 0.361). Treatment was not significant
either (F = 0.0061, p= 0.931).
DISCUSSION
In the present work we investigated biochemical, morphological
and behavioral alterations induced by the PA rat model at
P30, since this time point corresponds to the age of NDDs
onset in humans (Herrera-Marschitz et al., 2014, 2017). We
also examined the effect that the neuroprotective treatment
with PEA exerted at this sensitive time-window when deficits
become evident (Meredith et al., 2012). Interestingly, our findings
show vulnerability of CA1 hippocampal neurons to PA at P30.
These neurons showed clear signs of degeneration, including
NeuN fragmentation of the nucleus, cytoplasmic staining without
nuclear staining, and nuclear pyknosis. Neuronal cytoskeleton
was affected as it can be inferred from an excessive accumulation
of pNF-H/M and a significant reduction in MAP-2 marker. The
functional correlate was associated with changes in prototypical
behaviors, which indicate vertical exploration impairments and
altered anxiety levels. PEA treatment (10 mg/kg) within the
first hour of life could attenuate these alterations at P30, which
precede well-known long-term impairments induced in the PA
rat model (Capani et al., 2009; Saraceno et al., 2010, 2012;
Galeano et al., 2011, 2015; Muñiz et al., 2014).
In previous works from our laboratory, the effect of PA was
evaluated using both cesarean and vaginal fostered controls.
Blanco et al. (2015) reported no differences in most of the
behavioral, cellular and molecular parameters assessed using
cesarean and vaginal controls. The effect of PA at P30 was
also assessed using vaginal fostered control pups and major
differences were found between both groups (Saraceno et al.,
2016). Therefore, considering these results and the fact that
we subject animals to a severe PA (19min), we consider that
differences between groups can be attributed mainly to the
effect of PA insult. Additionally, in the present work, we mixed
asphyctic rats with control rats in order to provide the same
mother and postnatal environment, and asphyctic rats were well
accepted by these surrogate mothers (see Materials and Methods
section).
Neuronal Cytoskeleton Modifications
Induced by PA at P30
Previous studies have shown that neurofilaments change their
degree of phosphorylation after cerebral hypoxia-ischemia
(Mink and Johnston, 2000) and serve as clinical biomarkers
of hypoxic-ischemic encephalopathy (Douglas-Escobar et al.,
2010). Dendritic alterations are also a common finding under
glucose/oxygen deprivation (Park et al., 2008) and hypoxic-
ischemic injury (Zhu et al., 2003; Takita et al., 2004). A
40% decrease of MAP-2-positive cells/mm3 was observed
in organotypic hippocampal cultures from asphyxia-exposed
animals (Morales et al., 2007). Since MAP-2 is a cytoskeletal
protein, its expression depends on ATP concentration, which is
reduced as a result of hypoxia (Ashworth et al., 2003). Calpain-
induced proteolysis of MAP-2 may be an initial response to a
hypoxic insult (Johnson and Jope, 1992). In agreement with this
background, our results reveal a significant increase of pNF-
H/M and a reduction of MAP-2 as a result of PA at P30. These
findings suggest pNF-H/M and MAP-2 constitute promising
biomarkers of short-term PA-induced damage in CA1, which
can be considered as an initial degenerative process of neurons,
as it can be inferred from our electron microscopy analyses.
In addition, dendritic alterations (Matesic and Lin, 1994) and
aberrant accumulation of pNF-H/M (Dale and Garcia, 2012) are
well-known hallmarks of neurodegeneration in several diseases.
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Functional Correlate of Neuronal
Cytoskeletal Alterations at P30
Recent evidence suggests hyperphosphorylation of
neurofilaments (Chen et al., 2017) and decreased MAP-2
levels (Soares et al., 2016) in the hippocampus are correlated
with cognitive and anxiety dysfunctions in murine models of
neurodegeneration and global cerebral ischemia, respectively.
In the present study, PA-induced hippocampal accumulation of
pNF-H/M and reduction of MAP-2 at P30 exhibited a similar
behavioral correlate. PA induced a significant decrement in
time spent rearing, a hippocampal-dependent behavior which
accounts for vertical exploration in response to novelty (Lever
et al., 2006). We hypothesize exploration could have been
modulated by excessive grooming displayed by PA rats. Long
time spent grooming has been associated with increased anxiety
levels (Kalueff and Tuohimaa, 2005), which tend to interfere
on free exploration (Lever et al.). In addition, the significant
augmentation encountered in time spent HD suggests PA
induced an increase in risk assessment behaviors (RAB), which
might also alter exploratory activity.
Alterations in rearing, grooming and HD at P30 might
precede long-term impairments in locomotion and horizontal
exploration (Galeano et al., 2011). In fact, these PA-induced
modifications in prototypical behaviors at P30 could not be
attributed to impairments in locomotion or general activity,
since no differences were observed in number of line crossings,
time spent in closed arms, and total distance traveled in
OF and EPM tests. Unlike the OF and the EPM tests, the
IA task might not be sensitive to early changes induced by
PA. Aversive associative memory was not impaired at P30,
reproducing previous findings from our laboratory (Saraceno
et al., 2016).
Glial Response to PA at P30
Unlike pNF-H/M andMAP-2, GFAPmight not be an appropriate
marker at P30. No significant differences were observed in the
number of GFAP astrocytes or in GFAP expression 1 month
after PA. Similar results were reported in previous studies from
our laboratory (Saraceno et al., 2016), where we suggested
PA-induced modifications in astrocyte population might be
progressive and sustained long after PA. Astrogliosis is generally
reported in a tertiary phase post-insult, occurring months after
PA (Douglas-Escobar and Weiss, 2015). In this sense, we have
previously observed a markedly significant increase in the
number of GFAP immunoreactive astrocytes at P120 (Saraceno
et al., 2010). Consistent with our current and previous findings,
recent clinical evidence suggests GFAP is not an early marker of
injury in PA (Looney et al., 2015).
Neuroprotective Effect of PEA Treatment
PEA treatment (10 mg/kg) displayed protective effects by
attenuating PA-induced degeneration and cytoskeletal alterations
of CA1 neurons. As for microglia, even when PEA is produced by
microglial cells and has a great effect on their modulation (Walter
et al., 2003; Guida et al., 2017b), rodents subjected to hypoxic-
ischemic injury present low microglial activity at P30. Therefore,
the pharmacological inhibition of microglia at P30 could worsen
the outcome after PA (Ferrazzano et al., 2013). PEA could also
reverse exploration deficits and modulate anxiety levels at P30.
In vitro studies in organotypic hippocampal slices have shown
neuroprotective effects of PEA via PPAR-α (Koch et al., 2011;
Scuderi et al., 2012). This receptor and its endogenous ligand,
PEA, are involved in several cognitive and emotional processes
(Fidaleo et al., 2014).
Although PEA endogenous content tends to increase
around P30 in physiological conditions (Lee et al., 2013), a
dysregulation of NAEs signaling system is induced by PA at
this time point (Blanco et al., 2015; Holubiec et al., 2017).
One month after PA, the expression of enzymes responsible
for synthesis (diacylglycerol lipase-α–DAGL-α, and N-acyl-
phosphatidylethanolamine-NAPE-hydrolyzing phospholipase
D—NAPE-PLD) and degradation (fatty acid amide hydrolase—
FAAH) of PEA, and its receptor PPAR-α, is decreased in
hippocampal CA1 (Blanco et al.). Therefore, the neuroprotective
effects of PEA on PA we observed in CA1 at this time point might
be attributable to a counter regulation of this signaling system
through the exogenous administration of PEA. In addition,
hippocampal sensitivity to NAEs signaling might also contribute
to explain the neuroprotective action of PEA treatment in this
brain area and its dependent behaviors. Recent evidence has
supported the deleterious effects of NAEs dysregulationon
control of neurogenesis, neuronal death and gliosis, in a
regional-dependent manner, presenting the hippocampus
specific vulnerability (Rivera et al., 2015).
CONCLUSION
PEA treatment (10 mg/kg) within the first hour of life could
attenuate PA-induced alterations in CA1 neurons at P30,
including nuclear pyknosis, aberrant accumulation of pNF-
H/M in axons, and reductions in MAP-2 dendritic protein.
These effects were associated with significant improvements in
exploratory activity and a regulation of anxiety levels. Therefore,
PEA represents a putative neuroprotective agent for PA-induced
hippocampal alterations at P30. Future studies should focus on
the protective effect of PEA treatment on PA at earlier and later
developmental stages.
AUTHOR CONTRIBUTIONS
MIH: Writing and Investigation. LDU, NT-U, CFK, and JPL:
Investigation. FC: Supervision.
ACKNOWLEDGMENTS
This work was supported by grants to FC from CONICET (PIP
2016–2019 no. 0779), the University of Buenos Aires (UBACyT
2014–2017 no. 20720130100014BA), IBRO-PROLAB 2017 and
FONCyT (PICD 0031 2016-2020).
Frontiers in Neuroscience | www.frontiersin.org 10 March 2018 | Volume 12 | Article 145
Herrera et al. Neuroprotection With Palmitoylethanolamide in Perinatal Asphyxia
REFERENCES
Adcock, L. M., and Papile, L. A. (2008). Perinatal asphyxia.Manual Neonatal Care
518–528.
Ahmad, A., Crupi, R., Impellizzeri, D., Campolo, M., Marino, A., Esposito, E.,
et al. (2012a). Administration of palmitoylethanolamide (PEA) protects the
neurovascular unit and reduces secondary injury after traumatic brain injury
in mice. Brain Behav. Immun. 26, 1310–1321. doi: 10.1016/j.bbi.2012.07.021
Ahmad, A., Genovese, T., Impellizzeri, D., Crupi, R., Velardi, E., Marino, A.,
et al. (2012b). Reduction of ischemic brain injury by administration of
palmitoylethanolamide after transient middle cerebral artery occlusion in rats.
Brain Res. 1477, 45–58. doi: 10.1016/j.brainres.2012.08.006
Ashworth, S. L., Southgate, E. L., Sandoval, R. M., Meberg, P. J., Bamburg, J. R.,
and Molitoris, B. A. (2003). ADF/cofilin mediates actin cytoskeletal alterations
in LLC-PK cells during ATP depletion. Am. J. Physiol. Renal. Physiol. 284,
F852–F862. doi: 10.1152/ajprenal.00210.2002
Barkhuizen, M., Van den Hove, D. L., Vles, J. S., Steinbusch, H. W., Kramer,
B. W., and Gavilanes, A. W. (2017). 25 years of research on global
asphyxia in the immature rat brain. Neurosci. Biobehav. Rev. 75, 166–182.
doi: 10.1016/j.neubiorev.2017.01.042
Barros, D., Amaral, O. B., Izquierdo, I., Geracitano, L., do Carmo Bassols Raseira,
M., Henriques, A. T., et al. (2006). Behavioral and genoprotective effects of
Vaccinium berries intake in mice. Pharmacol. Biochem. Behav. 84, 229–234.
doi: 10.1016/j.pbb.2006.05.001
Blanco, D., García-Alix, A., Valverde, E., Tenorio, V., Vento, M., Cabañas, F., et al.
(2011). Neuroprotección con hipotermia en el recién nacido con encefalopatía
hipóxico-isquémica. Guía de estándares para su aplicación clínica. An Pediatr.
75, 341.e1–341.e20. doi: 10.1016/j.anpedi.2011.07.012
Blanco, E., Galeano, P., Holubiec, M. I., Romero, J. I., Logica, T., Rivera,
P., et al. (2015). Perinatal asphyxia results in altered expression of the
hippocampal acylethanolamide/endocannabinoid signaling system associated
to memory impairments in postweaned rats. Front. Neuroanat. 9:141.
doi: 10.3389/fnana.2015.00141
Bjelke, B., Andersson, K., Ögren, S. O., and Bolme, P. (1991). Asphyctic lesion:
proliferation of tyrosine hydroxylase-immunoreactive nerve cell bodies in the
rat substantia nigra and functional changes in dopamine neurotransmission.
Brain Res. 543, 1–9. doi: 10.1016/0006-8993(91)91041-X
Brenes, J. C., Padilla, M., and Fornaguera, J. (2009). A detailed analysis of
open-field habituation and behavioral and neurochemical antidepressant-
like effects in postweaning enriched rats. Behav. Brain Res. 197, 125–137.
doi: 10.1016/j.bbr.2008.08.014
Capani, F., Martone, M. E., Deerinck, T. J., and Ellisman, M. H. (2001). Selective
localization of high concentrations of F-actin in subpopulations of dendritic
spines in rat central nervous system: a three-dimensional electron microscopic
study. J. Comp. Neurol. 435, 156–170. doi: 10.1002/cne.1199
Capani, F., Saraceno, G. E., Botti, V., Aon-Bertolino, L., de Oliveira, D.M., Barreto,
G., et al. (2009). Protein ubiquitination in postsynaptic densities after hypoxia
in rat neostriatum is blocked by hypothermia. Exp. Neurol. 219, 404–413.
doi: 10.1016/j.expneurol.2009.06.007
Chen, S., Sun, J., Zhao, G., Guo, A., Chen, Y., Fu, R., et al. (2017).
Liraglutide improves water maze learning and memory performance
while reduces hyperphosphorylation of tau and neurofilaments in
APP/PS1/Tau triple transgenic mice. Neurochem. Res. 42, 2326–2335.
doi: 10.1007/s11064-017-2250-8
Coppola, M., and Mondola, R. (2013). Palmitoylethanolamide: from endogenous
cannabimimetic substance to innovativemedicine for the treatment of cannabis
dependence.Med. Hypotheses 81, 619–622. doi: 10.1016/j.mehy.2013.07.016
Dale, J. M., and Garcia, M. L. (2012). Neurofilament phosphorylation during
development and disease: which came first, the phosphorylation or the
accumulation?. J. Amino Acids 2012:382107. doi: 10.1155/2012/382107
D’Agostino, G., Russo, R., Avagliano, C., Cristiano, C., Meli, R., and Calignano,
A. (2012). Palmitoylethanolamide protects against the amyloid-β25-35-
induced learning and memory impairment in mice, an experimental
model of Alzheimer disease. Neuropsychopharmacology 37, 1784–1792.
doi: 10.1038/npp.2012.25
Douglas-Escobar, M., and Weiss, M. D. (2015). Hypoxic-ischemic
encephalopathy: a review for the clinician. JAMA Pediatr. 169, 397–403.
doi: 10.1001/jamapediatrics.2014.3269
Douglas-Escobar, M., Yang, C., Bennett, J., Shuster, J., Theriaque, D.,
Leibovici, A., et al. (2010).A pilot study of novel biomarkers in neonates
with hypoxic-ischemic encephalopathy. Pediatr. Res. 68, 531–536.
doi: 10.1203/PDR.0b013e3181f85a03
Ennaceur, A., and Delacour, J. (1988). A new one-trial test for neurobiological
studies of memory in rats.1: Behavioral data. Behav. Brain Res. 31, 47–59.
Esposito, E., Impellizzeri, D., Mazzon, E., Paterniti, I., and Cuzzocrea, S. (2012).
Neuroprotective activities of palmitoylethanolamide in an animal model of
Parkinson’s disease. PLoS ONE 7:e41880. doi: 10.1371/journal.pone.0041880
Esposito, E., Paterniti, I., Mazzon, E., Genovese, T., Di Paola, R., Galuppo, M.,
et al. (2011). Effects of palmitoylethanolamide on release of mast cell peptidases
and neurotrophic factors after spinal cord injury. Brain Behav. Immun. 25,
1099–1112. doi: 10.1016/j.bbi.2011.02.006
Ferrazzano, P., Chanana, V., Uluc, K., Fidan, E., Akture, E., Kintner, D.
B., et al. (2013). Age-dependent microglial activation in immature brains
after hypoxia-ischemia. CNS Neurol. Disord. Drug Targets 12, 338–349.
doi: 10.2174/1871527311312030007
Fezer, G. F., Matos, M. B. D., Nau, A. L., Zeigelboim, B. S., Marques, J.
M., and Liberalesso, P. B. N. (2017). Perinatal features of children
with autism sPectrum disorder. Rev. Paul. Pediatr. 35, 130–135.
doi: 10.1590/1984-0462/;2017;35;2;00003
Fidaleo, M., Fanelli, F., Paola Ceru, M., and Moreno, S. (2014).
Neuroprotective properties of peroxisome proliferator-activated receptor
alpha (PPARα) and its lipid ligands. Curr. Med. Chem. 21, 2803–2821.
doi: 10.2174/0929867321666140303143455
Galeano, P., Blanco Calvo, E., Madureira de Oliveira, D., Cuenya, L., Kamenetzky,
G. V., Mustaca, A. E., et al. (2011). Long-lasting effects of perinatal asphyxia
on exploration, memory and incentive downshift. Int. J. Dev. Neurosci. 29,
609–619. doi: 10.1016/j.ijdevneu.2011.05.002
Galeano, P., Blanco, E., Logica Tornatore, T., Romero, J. I., Holubiec, M. I.,
Rodríguez de Fonseca, F., et al. (2015). Life-long environmental enrichment
counteracts spatial learning, reference and working memory deficits in middle-
aged rats subjected to perinatal asphyxia. Front. Behav. Neurosci. 8:406.
doi: 10.3389/fnbeh.2014.00406
Genovese, T., Esposito, E., Mazzon, E., Di Paola, R., Meli, R., Bramanti, P., et al.
(2008). Effects of palmitoylethanolamide on signaling pathways implicated in
the development of spinal cord injury. J. Pharmacol. Exp. Ther. 326, 12–23.
doi: 10.1124/jpet.108.136903
Guida, F., Boccella, S., Iannotta, M., De Gregorio, D., Giordano, C., Belardo,
C., et al. (2017a). Palmitoylethanolamide reduces neuropsychiatric behaviors
by restoring cortical electrophysiological activity in a mouse model of mild
traumatic brain injury. Front. Pharmacol. 8:95. doi: 10.3389/fphar.2017.00095
Guida, F., Luongo, L., Boccella, S., Giordano, M. E., Romano, R., Bellini, G., et al.
(2017b). Palmitoylethanolamide induces microglia changes associated with
increased migration and phagocytic activity: involvement of the CB2 receptor.
Sci. Rep. 7:375. doi: 10.1038/s41598-017-00342-1
Herrera, M., Kölliker-Frers, R., Barreto, G., Blanco, E., and Capani, F. (2016). Glial
Modulation by N-acylethanolamides in Brain Injury and Neurodegeneration.
Front. Aging Neurosci. 8:81. doi: 10.3389/fnagi.2016.00081
Herrera, M., Otero-Losada, M., Udovin, L., Kusnier, C., Kölliker-Frers, R., de
Souza, W., et al. (2017). Could perinatal asphyxia induce a synaptopathy?
new highlights from an experimental model. Neural Plast 2017:3436943.
doi: 10.1155/2017/3436943
Herrera-Marschitz, M., Morales, P., Leyton, L., Bustamante, D., Klawitter, V.,
and Espina-Marchant, P., et al. (2011). Perinatal asphyxia: current status and
approaches towards neuroprotective strategies, with focus on sentinel proteins.
Neurotox. Res. 19, 603–627. doi: 10.1007/s12640-010-9208-9
Herrera-Marschitz, M., Neira-Pena, T., Rojas-Mancilla, E., Espina-Marchant, P.,
Esmar, D., and Perez, R., et al. (2014). Perinatal asphyxia: CNS development
and deficits with delayed onset. Front. Neurosci. 8:47. doi: 10.3389/fnins.2014.
00047
Herrera-Marschitz, M., Perez-Lobos, R., Lespay-Rebolledo, C., Tapia-Bustos, A.,
Casanova-Ortiz, E., Morales, P., et al. (2017). Targeting sentinel proteins
and extrasynaptic glutamate receptors: a therapeutic strategy for preventing
the effects elicited by perinatal asphyxia? Neurotox Res. 33, 461-473.
doi: 10.1007/s12640-017-9795-9
Holubiec, M. I., Romero, J. I., Blanco, E., Tornatore, T. L., Suarez, J., de Fonseca,
F., et al. (2017). Acylethanolamides and endocannabinoid signaling system
Frontiers in Neuroscience | www.frontiersin.org 11 March 2018 | Volume 12 | Article 145
Herrera et al. Neuroprotection With Palmitoylethanolamide in Perinatal Asphyxia
in dorsal striatum of rats exposed to perinatal asphyxia. Neurosci. Lett. 653,
269–275. doi: 10.1016/j.neulet.2017.05.068
Izquierdo, I., and Medina, J. H. (1997). Memory formation: the sequence
of biochemical events in the hippocampus and its connection to
activity in other brain structures. Neurobiol. Learn. Mem. 68, 285–316.
doi: 10.1006/nlme.1997.3799
Johnson, G. V., and Jope, R. S. (1992). The role of microtubule-associated protein 2
(MAP-2) in neuronal growth, plasticity, and degeneration. J. Neurosci. Res. 33,
505–512. doi: 10.1002/jnr.490330402
Kalueff, A. V., and Tuohimaa, P. (2005). Mouse grooming microstructure is a
reliable anxiety marker bidirectionally sensitive to GABAergic drugs. Eur. J.
Pharmacol. 508, 147–153. doi: 10.1016/j.ejphar.2004.11.054
Koch, M., Kreutz, S., Böttger, C., Benz, A., Maronde, E., Ghadban, C.,
et al. (2011). Palmitoylethanolamide protects dentate gyrus granule cells via
peroxisome proliferator-activated receptor-alpha. Neurotox. Res. 19, 330–340.
doi: 10.1007/s12640-010-9166-2
Kuzniewicz, M. W., Wi, S., Qian, Y., Walsh, E. M., Armstrong, M. A,
and Croen, L. A. (2014). Prevalence and neonatal factors associated with
autism spectrum disorders in preterm infants. J. Pediatr. 164, 20–25.
doi: 10.1016/j.jpeds.2013.09.021
Lambert, D. M., Vandevoorde, S., Diependaele, G., Govaerts, S. J., and
Robert, A. R. (2001). Anticonvulsant activity of N-palmitoylethanolamide,
a putative endocannabinoid, in mice. Epilepsia 42, 321–327.
doi: 10.1046/j.1528-1157.2001.41499.x
Lee, T. T., Hill, M. N., Hillard, C. J., and Gorzalka, B. B. (2013). Temporal
changes in N-acylethanolamine content and metabolism throughout the peri-
adolescent period. Synapse 67, 4–10. doi: 10.1002/syn.21609
Lever, C., Burton, S., and O’Keefe, J. (2006). Rearing on hind legs, environmental
novelty, and the hippocampal formation. Rev. Neurosci. 17, 111–134.
doi: 10.1515/REVNEURO.2006.17.1-2.111
Lorenzini, C. A., Baldi, E., Bucherelli, C., Sacchetti, B., and Tassoni, G. (1996).
Role of dorsal hippocampus in acquisition, consolidation and retrieval of rat’s
passive avoidance response: a tetrodotoxin functional inactivation study. Brain
Res. 730, 32–39. doi: 10.1016/0006-8993(96)00427-1
Looney, A. M., Ahearne, C., Boylan, G. B., and Murray, D. M. (2015).
Glial fibrillary acidic protein is not an early marker of injury in
perinatal asphyxia and hypoxic–ischemic encephalopathy. Front. Neurol. 6:264.
doi: 10.3389/fneur.2015.00264
Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., et al. (2005).
The nuclear receptor peroxisome proliferator-activated receptor-α mediates
the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67,
15–19. doi: 10.1124/mol.104.006353
Matesic, D. F., and Lin, R. (1994). Microtubule-Associated Protein 2 as
an Early Indicator of Ischemia-Induced Neurodegeneration in the Gerbil
Forebrain. J. Neurochem. 63, 1012–1020. doi: 10.1046/j.1471-4159.1994.6303
1012.x
Melis, M., Pillolla, G., Luchicchi, A., Muntoni, A. L., Yasar, S., Goldberg, S. R.,
et al. (2008). Endogenous fatty acid ethanolamides suppress nicotine-induced
activation of mesolimbic dopamine neurons through nuclear receptors. J.
Neurosci. 28, 13985–13994. doi: 10.1523/JNEUROSCI.3221-08.2008
Meredith, R. M., Dawitz, J., and Kramvis, I. (2012). Sensitive time-windows for
susceptibility in neurodevelopmental disorders. Trends Neurosci. 35, 335–344.
doi: 10.1016/j.tins.2012.03.005
Molina, S. J., Capani, F., and Guelman, L. R. (2016). Noise exposure of immature
rats can induce different age-dependent extra-auditory alterations that can be
partially restored by rearing animals in an enriched environment. Brain Res.
1636, 52–61. doi: 10.1016/j.brainres.2016.01.050
Montgomery, K. C. (1955). The relation between fear induced by novel
stimulation and exploratory drive. J. Comp. Physiol. Psychol. 48, 254–260.
doi: 10.1037/h0043788
Morales, P., Bustamante, D., Espina-Marchant, P., Neira-Peña, T., Gutiérrez-
Hernández, M. A., Allende-Castro, C., et al. (2011). Pathophysiology of
perinatal asphyxia: can we predict and improve individual outcomes? EPMA
J. 2, 211–230. doi: 10.1007/s13167-011-0100-3
Morales, P., Huaiquin, P., Bustamante, D., Fiedler, J., and Herrera-Marschitz,
M. (2007). Perinatal asphyxia induces neurogenesis in hippocampus: an
organotypic culture study. Neurotox. Res. 12, 81–84. doi: 10.1007/BF030
33903
Mink, R. B., and Johnston, J. A. (2000). Changes in brain neurofilament and beta-
tubulin proteins after cerebral hypoxia-ischemia in rabbits. Pathobiology 68,
43–52. doi: 10.1159/000028114
Muñiz, J., Romero, J., Holubiec, M., Barreto, G., González, J., Saint-Martin,
M., et al. (2014). Neuroprotective effects of hypothermia on synaptic actin
cytoskeletal changes induced by perinatal asphyxia. Brain Res. 1563, 81–90.
doi: 10.1016/j.brainres.2014.03.023
Park, S. J., Jung, Y. J., Kim, Y. A., Lee-Kang, J. H., and Lee, K. E.
(2008). Glucose/oxygen deprivation and reperfusion upregulate SNAREs and
complexin in organotypic hippocampal slice cultures. Neuropathology 28,
612–620. doi: 10.1111/j.1440-1789.2008.00927.x
Perna, R., and Cooper, D. (2012). Perinatal cyanosis: long-term cognitive
sequelae and behavioral consequences. Appl. Neuropsychol. Child 1, 48–52.
doi: 10.1080/09084282.2011.643946
Petito, C. K., and Pulsinelli, W. A. (1984). Delayed neuronal recovery and
neuronal death in rat hippocampus following severe cerebral ischemia: possible
relationship to abnormalities in neuronal processes. J. Cereb. Blood FlowMetab.
4, 194–205. doi: 10.1038/jcbfm.1984.28
Petrosino, S., and Di Marzo, V. (2017). The pharmacology of
palmitoylethanolamide and first data on the therapeutic efficacy of some of its
new formulations. Br. J. Pharmacol. 174, 1349–1365. doi: 10.1111/bph.13580
Petrosino, S., Iuvone, T., and Di Marzo, V. (2010). N-palmitoyl-ethanolamine:
Biochemistry and new therapeutic opportunities. Biochimie 92, 724–727.
doi: 10.1016/j.biochi.2010.01.006
Pulsinelli, W. A. (1985). Selective neuronal vulnerability: morphological and
molecular characteristics. Prog. Brain Res. 63, 29–37.
Re, G., Barbero, R., Miolo, A., and Di Marzo, V. (2007). Palmitoylethanolamide,
endocannabinoids and related cannabimimetic compounds in protection
against tissue inflammation and pain: potential use in companion animals. Vet.
J. 173, 21–30. doi: 10.1016/j.tvjl.2005.10.003
Rivera, P., Bindila, L., Pastor, A., Pérez-Martín, M., Pavón, F. J., Serrano, A., et al.
(2015). Pharmacological blockade of the fatty acid amide hydrolase (FAAH)
alters neural proliferation, apoptosis and gliosis in the rat hippocampus,
hypothalamus and striatum in a negative energy context. Front. Cell. Neurosci.
9:98. doi: 10.3389/fncel.2015.00098
Robertson, C. L., Puskar, A., Hoffman, G. E., Murphy, A. Z., Saraswati, M.,
and Fiskum, G. (2006). Physiologic progesterone reduces mitochondrial
dysfunction and hippocampal cell loss after traumatic brain injury in female
rats. Exp. Neurol. 197, 235–243. doi: 10.1016/j.expneurol.2005.09.014
Rodgers, R. J., and Cole, J. C. (1993). Influence of social isolation, gender, strain,
and prior novelty on plus-maze behaviour in mice. Physiol. Behav. 54, 729–736.
doi: 10.1016/0031-9384(93)90084-S
Rojas, D. C., Smith, J. A., Benkers, T. L., Camou, S. L., Reite, M. L.,
and Rogers, S. J. (2004). Hippocampus and amygdala volumes in parents
of children with autistic disorder. Am. J. Psychiatry. 161, 2038–2044.
doi: 10.1176/appi.ajp.161.11.2038
Saraceno, G. E., Bertolino, M. L., Galeano, P., Romero, J. I., Garcia-Segura, L.
M., and Capani, F. (2010). Estradiol therapy in adulthood reverses glial and
neuronal alterations caused by perinatal asphyxia. Exp. Neurol. 223, 615–622.
doi: 10.1016/j.expneurol.2010.02.010
Saraceno, G. E., Caceres, L. G., Guelman, L. R., Castilla, R., Udovin, L. D.,
Ellisman, M. H., et al. (2016). Consequences of excessive plasticity in the
hippocampus induced by perinatal asphyxia. Exp. Neurol. 286, 116–123.
doi: 10.1016/j.expneurol.2016.08.017
Saraceno, G. E., Castilla, R., Barreto, G. E., Gonzalez, J., Kölliker-Frers, R. A.,
and Capani, F. (2012). Hippocampal dendritic spines modifications induced
by perinatal asphyxia. Neural Plast. 2012:873532. doi: 10.1155/2012/873532
Sayd, A., Antón,M., Alén, F., Caso, J. R., Pavón, J., Leza, J. C., et al. (2014). Systemic
administration of oleoylethanolamide protects from neuroinflammation and
anhedonia induced by LPS in rats. Int. J. Neuropsychopharmacol. 18:pyu111.
doi: 10.1093/ijnp/pyu111
Schieve, L., Tian, L., Baio, J., Rankin, K., Rosenberg, D., and Wiggins,
L., et al. (2014). Population attributable fractions for three perinatal
risk factors for autism spectrum disorders, 2002 and 2008 autism and
developmental disabilities monitoring network. Ann. Epidemiol. 24, 260–266.
doi: 10.1016/j.annepidem.2013.12.014
Scuderi, C., Stecca, C., Valenza, M., Ratano, P., Bronzuoli, M. R., Bartoli,
S., et al. (2014). Palmitoylethanolamide controls reactive gliosis and exerts
Frontiers in Neuroscience | www.frontiersin.org 12 March 2018 | Volume 12 | Article 145
Herrera et al. Neuroprotection With Palmitoylethanolamide in Perinatal Asphyxia
neuroprotective functions in a rat model of Alzheimer’s disease. Cell Death Dis.
5:e1419. doi: 10.1038/cddis.2014.376
Scuderi, C., Valenza, M., Stecca, C., Esposito, G., Carratù, M. R., and
Steardo, L. (2012). Palmitoylethanolamide exerts neuroprotective effects
in mixed neuroglial cultures and organotypic hippocampal slices via
peroxisome proliferator-activated receptor-α. J. Neuroinflammation 9:49.
doi: 10.1186/1742-2094-9-21
Semple, B. D., Blomgren, K., Gimlin, K., Ferriero, D. M., and Noble-Haeusslein, L.
J. (2013). Brain development in rodents and humans: Identifying benchmarks
of maturation and vulnerability to injury across species. Prog. Neurobiol. 106,
1–16. doi: 10.1016/j.pneurobio.2013.04.001
Sheerin, A. H., Zhang, X., Saucier, D. M., and Corcoran, M. E. (2004). Selective
antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid.
Epilepsia 45, 1184–1188. doi: 10.1111/j.0013-9580.2004.16.x
Soares, L. M., De Vry, J., Steinbusch, H. W., Milani, H., Prickaerts, J.,
and Weffort de Oliveira, R. M. (2016). Rolipram improves cognition,
reduces anxiety-and despair-like behaviors and impacts hippocampal
neuroplasticity after transient global cerebral ischemia. Neuroscience 326,
69–83. doi: 10.1016/j.neuroscience.2016.03.062
Takita, M., Puka-Sundvall, M., Miyakawa, A., and Hagberg, H. (2004).
In vivo calcium imaging of cerebral cortex in hypoxia–ischemia followed
by developmental stage-specific injury in rats. Neurosci. Res. 48, 169–173.
doi: 10.1016/j.neures.2003.10.016
Van de Berg, W. D., Blokland, A., Cuello, A. C., Schmitz, C., Vreuls,
W., Steinbusch, H. W., et al. (2000). Perinatal asphyxia results in
changes in presynaptic bouton number in striatum and cerebral cortex—
a stereological and behavioral analysis. J. Chem. Neuroanat. 20, 71–82.
doi: 10.1016/s0891-0618(00) 00078-8
van Handel, M., Swaab, H., de Vries, L., and Jongmans, M. (2007). Long-
term cognitive and behavioral consequences of neonatal encephalopathy
following perinatal asphyxia: a review. Eur. J. Pediatr. 166, 645–654.
doi: 10.1007/s00431-007-0437-8
Vianna, M. R., Alonso, M., Viola, H., Quevedo, J., de Paris, F., Furman, M.,
et al. (2000). Role of hippocampal signaling pathways in long-term memory
formation of a nonassociative learning task in the rat. Learn. Mem. 7, 333–340.
doi: 10.1101/lm.34600
Violle, N., Balandras, F., Le Roux, Y., Desor, D., and Schroeder, H. (2009).
Variations in illumination, closed wall transparency and/or extramaze space
influence both baseline anxiety and response to diazepam in the rat
elevated plus-maze. Behav. Brain Res. 203, 35–42. doi: 10.1016/j.bbr.2009.
04.015
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., et al. (2003).
Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J.
Neurosci. 23, 1398–1405.
Zhu, C., Qiu, L., Wang, X., Hallin, U., Candé, C., Kroemer, G., et al.
(2003). Involvement of apoptosis-inducing factor in neuronal death after
hypoxia-ischemia in the neonatal rat brain. J. Neurochem. 86, 306–317.
doi: 10.1046/j.1471-4159.2003.01832.x
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Herrera, Udovin, Toro-Urrego, Kusnier, Luaces and Capani. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 13 March 2018 | Volume 12 | Article 145
